StimCell's eBalance(R) Technology Demonstrates Significant Enhancement of Mitochondrial Function in Neuronal Study
Longer-term stimulation studies and molecular analyses remain ongoing after preliminary results in cultured rat sensory neurons.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
StimCell Energetics (STME) announced preliminary findings showing improved mitochondrial function with eBalance microcurrent stimulation in cultured healthy adult rat sensory neurons.
The study, conducted with St. Boniface Hospital Albrechtsen Research Centre, reported increases versus unstimulated controls of 49% in basal respiration, 119% in maximal respiration and 174% in spare respiratory capacity, the ability to meet additional energy demand. Extracellular acidification, a measure used to assess cellular energy production, increased approximately 85-90% at peak stimulation. All four changes were statistically significant, with n=5. These are initial experimental results; longer-term stimulation studies and complementary molecular analyses are ongoing.
Positive
- Minor pointBasal respiration increased 49% versus unstimulated controls (p < 0.005) in cultured rat sensory neurons.
- Minor pointMaximal respiration increased 119% versus unstimulated controls (p < 0.0001) in cultured rat sensory neurons.
- Minor pointSpare respiratory capacity increased 174% versus unstimulated controls (p < 0.0005) in cultured rat sensory neurons.
- Minor pointExtracellular acidification increased approximately 85-90% at peak stimulation versus unstimulated controls (p < 0.0001).
- Minor point. Forward-looking: it has not happened yet and may not happen.Longer-term stimulation studies and complementary molecular analyses are ongoing; discussions to extend the research program are underway.
Negative
- Minor pointResults are preliminary, from initial experimental rounds in cultured healthy adult rat sensory neurons, with n=5.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, BC / ACCESS Newswire / November 12, 2026 / StimCell Energetics Inc. (OTCQB:STME) ("StimCell" or the "Company"), a biotech pioneer targeting cellular energy to enhance wellness, anti-aging, and longevity, today announced positive preliminary results from its research collaboration with the St. Boniface Hospital Albrechtsen Research Centre (affiliated with the University of Manitoba) and Principal Investigator Professor Paul Fernyhough.
The study, conducted under the service agreement announced in December 2025, evaluated the effects of StimCell's proprietary eBalance® microcurrent technology on mitochondrial function in cultured healthy adult rat sensory neurons. Using established Seahorse-based bioenergetic assays in Dr. Fernyhough's laboratory, the research measured oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) to assess key parameters of cellular energy production.
Initial results demonstrate that eBalance® stimulation produces statistically significant improvements in mitochondrial respiratory function compared with unstimulated controls (mean ± SEM, n=5; one-way ANOVA with Dunnett's post hoc test):
- Basal respiration was significantly elevated by
49% (p < 0.005) - Maximal respiration increased by
119% (p < 0.0001) - Spare respiratory capacity was substantially enhanced by
174% (p < 0.0005) - ECAR at peak stimulation was also significantly higher by approximately 85
-90% (p < 0.0001), indicating elevated glycolytic activity
These findings indicate that eBalance® stimulation increases both the baseline energy output of sensory neurons and their capacity to respond to increased energy demand. Spare respiratory capacity, in particular, reflects the ability of mitochondria to meet sudden or sustained energy requirements, a parameter frequently impaired in conditions associated with mitochondrial dysfunction.
"These preliminary data are very promising and demonstrate a clear, statistically significant effect of eBalance® stimulation on multiple parameters of mitochondrial function in healthy adult rat sensory neurons," said Professor Paul Fernyhough. "Sensory neurons derived from adult rat dorsal root ganglia are a well-established experimental model that closely parallels human sensory neurons in their morphology and physiology. Given the central role of mitochondrial bioenergetics in neuronal health and the pathogenesis of diabetic neuropathy, further investigation of these findings is warranted and underway."
Mitochondrial impairment is a well-documented feature of aging, diabetic neuropathy, and other neurodegenerative processes. Enhancing mitochondrial bioenergetics in sensory neurons is therefore of particular scientific and potential clinical interest. The magnitude of the improvements observed in this preliminary work is consistent with beneficial bioenergetic shifts previously reported in the literature with established interventions such as insulin and neurotrophic factors in similar neuronal models.
"We are very pleased with these early results from Dr. Fernyhough's laboratory," said David Jeffs, CEO of StimCell Energetics. "The ability of our eBalance® technology to produce measurable, statistically significant improvements in mitochondrial performance in a rigorous academic setting is an important milestone. It strengthens the scientific foundation of our platform and supports our broader goal of developing practical tools that help eBalance® users support cellular energy, wellness, and healthy aging."
The Company notes that these are preliminary results from initial experimental rounds. Additional analyses, including longer-term stimulation studies and complementary molecular assays, are ongoing and the Company is currently in discussions to extend its research program. A comprehensive report is expected upon completion of the full experimental program.
About StimCell Energetics Inc.
StimCell Energetics Inc. is a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness and alleviate health complications including, but not limited to: aging, insulin sensitivity, high blood pressure, neuropathy and kidney function. The Company's main focus is on continued research and development of its eBalance® Technology and its eBalance® Home System.
On behalf of the Board of Directors of StimCell Energetics Inc.
David Jeffs
CEO, Director
For further information:
info@stimcell.com
www.StimCell.com
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. Except as required by law, StimCell Energetics Inc. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that StimCell Energetics Inc. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
SOURCE: StimCell Energetics
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did StimCell's eBalance neuronal study show?
eBalance stimulation increased basal respiration by 49%, maximal respiration by 119% and spare respiratory capacity by 174% versus unstimulated controls in cultured healthy adult rat sensory neurons. Extracellular acidification increased approximately 85-90% at peak stimulation. The preliminary results were statistically significant, with n=5.
What are the next steps for StimCell's eBalance research?
Longer-term stimulation studies and complementary molecular analyses are ongoing, and StimCell is discussing an extension of the research program. The company expects a comprehensive report upon completion of the full experimental program.